TNFRSF11B and osteoporosis: While a number of potential targeting approaches are under investigation (RANK-Fc, OPG-Fc, OPG peptidomimetics, RANKL vaccination) [16], the monoclonal RANKL inhibiting antibody denosumab is currently the most established targeted agent and has been approved for the treatment of osteoporosis and bone metastases.